Details of the Drug Combination

General Information of Drug Combination (ID: DC13PCS)

Drug Combination Name
Rufinamide Paromomycin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Rufinamide   DMWE60C Paromomycin   DM1AGXN
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.37
Bliss Independence Score: 4.37
Loewe Additivity Score: 18.53
LHighest Single Agent (HSA) Score: 18.53

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rufinamide
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved (orphan drug) [2]
Pediatric lennox-gastaut syndrome 8A62.1 Approved [3]
Seizure disorder 8A6Z Approved [2]
Rufinamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [6]
------------------------------------------------------------------------------------
Rufinamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [7]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [4]
Hepatic coma N.A. Approved [4]
Intestinal amebiasis 1A36 Approved [5]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [8]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
3 Clinical pipeline report, company report or official report of Eisai.
4 Paromomycin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
6 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
7 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
8 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
9 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.